Product Name

Streptokinase from β-hemolytic Streptococcus (Lancefield Group C)

General deion

Streptokinase from β-hemolytic Streptococcus, or Streptokinase from Streptococcus hemolyticus, is effective in thrombolytic therapy.

Synonym

Streptokinase from Streptococcus hemolyticus

Assay

≥3,000 units/mg solid

CAS Number

9002-01-1

MDL number

MFCD00082037

Suitability

BioReagent

l Physical and Chemical Information

Appearance

Off-White to Light Yellow to Light Beige lyophilized powder

Physical form

Lyophilized powder containing ~50% total protein by biuret and sodium glutamate. Total protein composed of enzyme protein and human serum albumin.

l Biological Information

Application

Streptokinase is commonly used as a thrombolytic agent in the therapy of ischemic stroke. This therapy carries the important risk of intracerebral hemorrhage. Streptokinase is also used in the treatment of complicated parapneumonic effusions and empyema where adverse reactions, allergic type, are rare. Streptokinase has been used in a study to compare primary coronary intervention and thrombolytic therapy in myocardial infarction patients.

Preparation Note

Lyophilized powder containing ~50% total protein by biuret and sodium glutamate. Total protein composed of enzyme protein and human serum albumin.

Unit Definition

One unit will liquify a standard clot of fibrinogen, plasminogen, and thrombin at pH 7.5 at 37 °C in 10 min.

l Storage

Storage temp.

-20°C

l Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses.

l References

1. http://www.drugbank.ca

2. https://ncit.nci.nih.gov

3. https://www.ncbi.nlm.nih.gov